Log In
Print this Print this

Anti-CD19 chimeric antigen receptor (CAR) T cells

  Manage Alerts
Collapse Summary General Information
Company Kite Pharma Inc.
DescriptionHuman chimeric antigen receptor (CAR) T cells targeting CD19
Molecular Target CD19
Mechanism of Action 
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase I
Standard IndicationB cell lymphoma
Indication DetailsTreat diffuse large B cell lymphoma (DLBCL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today